Eltrombopag (Revolade) is a thrombopoietin receptor agonist developed by GlaxoSmithKline, primarily indicated for the treatment of thrombocytopenia caused by various factors.

Indications for Eltrombopag (Revolade)

Chronic Immune Thrombocytopenia (ITP)

Eltrombopag is indicated for the treatment of chronic immune (idiopathic) thrombocytopenia in pediatric patients aged 1 year and older and adult patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

This medication should only be used in patient populations where the degree of thrombocytopenia and clinical condition increase the risk of bleeding.

Thrombocytopenia Associated with Chronic Hepatitis C

For patients with chronic hepatitis C, eltrombopag can be used to treat thrombocytopenia, enabling patients to initiate and maintain interferon-based treatment regimens.

This medication is only suitable for patients where the degree of thrombocytopenia prevents the initiation of interferon treatment or limits the ability to maintain interferon treatment.

Severe Aplastic Anemia

Eltrombopag is also approved for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Specifications and Properties of Eltrombopag (Revolade)

Tablets

12.5mg tablets: Round, biconvex, white film-coated tablets, engraved with "GSMZ1" and "12.5" on one side.

25mg tablets: Round, biconvex, orange film-coated tablets, engraved with "GSNX3" and "25" on one side.

50mg tablets: Round, biconvex, blue film-coated tablets, engraved with "GSUFU" and "50" on one side.

75mg tablets: Round, biconvex, pink film-coated tablets, engraved with "GSFFS" and "75" on one side.

100mg tablets: Round, biconvex, green film-coated tablets, engraved with "GS1L5" on one side.

Oral Suspension

Eltrombopag is also available as an oral suspension with a strength of 25mg per sachet. It is a reddish-brown to yellow powder that needs to be reconstituted with water before use.

The oral suspension is particularly suitable for patients with swallowing difficulties or pediatric patients. However, it should be noted that the reconstituted suspension should be administered immediately, and any suspension not used within 30 minutes should be discarded.

Storage Methods for Eltrombopag (Revolade)

Storage Conditions

Both eltrombopag tablets and oral suspension powder should be stored at room temperature (20–25°C), with short-term storage allowed in an environment of 15–30°C.

It is important to keep the medication out of the reach of children and protect it from direct sunlight and humid environments.

The oral suspension powder should remain in its intact packaging to prevent moisture absorption before reconstitution.